Non-Sponsored Content
By: News Feed | Last updated: 10th May 2019 | In: Gastrointestinal Cancer, Targeted Therapies, US FDA Onc\Haem Approvals
Article Keywords
AFP, Cyramza, Eli Lilly, ramucirumab, sorafenib
On 10 May 2019, the FDA approved single agent ramucirumab (Cyramza®, Eli Lilly) for the treatment of hepatocellular carcinoma (HCC) patients previously treated with sorafenib and who have an alpha-fetoproteintein (AFP) of ≥400 ng/mL.
REACH-2
The FDA approval was based on data of the multinational, double-blind, placebo-controlled, multicentre REACH‑2 (NCT02435433) study that randomised 292 advanced HCC patients with AFP ≥400 ng/mL and disease progression on or after prior sorafenib or intolerant to sorafenib. Participants were randomised (2:1) to receive either ramucirumab plus best supportive care (BSC) or placebo plus BSC until disease progression or the occurrence of unacceptable toxicity. The primary efficacy endpoint was the overall survival (OS).
The REACH-2 trial showed a significant improvement in the estimated median OS, measuring 8.5 months (range: 7.0-10.6) for patients receiving ramucirumab plus BSC vs 7.3 months (range: 5.4-9.1) for patients receiving placebo plus BSC (HR=0.71; 95% CI, 0.53-0.95; P=0.020).
Safety
Common adverse reactions in ≥15% of HCC patients receiving single-agent ramucirumab, and with a ≥2% higher incidence when compared to placebo, included fatigue, peripheral oedema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. Common laboratory abnormalities occurring in ≥30% of patients, and with a ≥ 2% higher incidence when compared to placebo) were hypoalbuminemia, hyponatremia, and thrombocytopenia.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2019 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE
Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
© Copyright 2019 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!